Tweets
Aortitis: Let’s review the differential for #aortitis including Non-Infectious and Infectious Causes!
@febrilepodcast x @RheumOnePagers | created by @MithuRheum @swinndong
#IDTwitter #RheumTwitter #FOAMed https://t.co/pR0iTls4PK
Rheum OnePagers @RheumOnePagers ( View Tweet )
4 years 10 months ago
New study on #COVID19Vaccine in autoimmune cytopenias
🩸7.4% had clinically significant ⬇️ in counts
🩸 All successfully managed w/steroids & transfusion
🩸 Mild ⬇️ in 10% AIHA and 20% ITP
⭐️Vaccination safe with close monitoring⭐️
https://t.co/qGZe6LiPKz
AmericanJournalofHematology @AjHematology ( View Tweet )
4 years 10 months ago
Pooled analysis of the DISCOVER-1 and DISCOVER-2 trials have shown that guselkumab, an IL-23 inhibitor, was effective and safe in psoriatic arthritis (PsA) patients with axial involvement and imaging-confirmed sacroiliitis. #RheumNow
https://t.co/yLCxyC1oLr https://t.co/Uloqx2phlh
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
The #1 question I get from new consults: “How did I get arthritis?” Here is my list of 11 drugs (or drug classes) known to cause arthritis or rheumatic disorders (as an unintended consequence). #RheumNow https://t.co/GsV0Qj9ENr https://t.co/IrTkY5yFdY
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
Study of 435 #SLE pts seen during the pandemic. Comparing those seen F2F vs telemedicine, there was no significant difference in SLE disease activity (by SLEDAI-2K) or SLE flare rates or steroid prescribing between visit types https://t.co/kscU9CbqVM
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
Prescribe antimalarial dosages at 5 mg/kg/d or less.... A baseline retinal exam w/ optical coherence tomography should be performed w/in 6 mos...to rule out confounding Dz. Pts at low risk for retinopathy do not require annual screening until 5 years.. https://t.co/l3sCxOJLNJ
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
Encouraging DBRPCT of Rituximab in #PMR: 116 screened, 49 enrolled, 47 completed: 23 on RTX vs 24 on PBO. Steroid-free remission at 21 wks seen with 11/23 (48%) RTX pts vs 5/24 (21%) on PBO (p=0·049). Infusion Rxns: 10 RTX vs 3 PBO); 1 SAE (PE) on RTX https://t.co/U2ZGNrpi0i
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
JAKi vs bDMARDS in Real World Data
https://t.co/7P6zvp45vH
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
Pregnancies exposed to ixekizumab (from Eli Lilly Global Safety Database) found 193 pts with psoriasis, PsA, or axSpA who were IXE exposed. Live births reported for 53.8 and 61.1% of known outcomes. No congenital malformations seen. https://t.co/M1rvCH81hT
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
The EMA has recommended Nucala (mepolizumab) as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA) https://t.co/0aVoDpaTPT
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
FDA approves Jakafi for chronic GVHD. Ruxolitinib (Jakafi, Incyte), an oral Janus kinase 1/2 inhibitor, previously received approval for treatment of patients aged 12 years or older with steroid-refractory acute GVHD. https://t.co/isItDebNZ8
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
Insurance data (biologics only given to refractory pts) study of 249 (TKR) & 159 (THR) surgeries in ~6000 #RA pts. Pts on biologics had signif less TKR (aHR: 0.55) & THR (0.63) vs higher rates if on MTX, steroids, biologic switch or APL syndr https://t.co/4rwuYswqz7
Links:
Dr. John Cush @RheumNow ( View Tweet )
4 years 10 months ago
